Overview

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects of VSA003 in Chinese Adult Healthy Volunteers

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst
Phase:
Phase 1
Details
Lead Sponsor:
Visirna Therapeutics HK Limited